COMP <GO>
ADMA vs MRK // FREE CASH FLOW YIELD
ADMA Biologics Inc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ADMA 8
— MRK 4
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $11.41 (-2.89%) • MKT CAP: $2.63B
fcf-yield
1.06%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | 74.80% | -17.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | 20.70% | +12.20 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.4x | 15.3x | -2.90 | ADMA | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.06% | 3.42% | -2.36 | MRK | /fcf-yield <GO> |
| Operating Margin | 37.50% | 34.30% | +3.20 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 28.80% | 28.10% | +0.70 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 1.30% | +18.30 | ADMA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.98 | 5.19 | +7.79 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.9 | 51.7 | +16.20 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | 18.4x | -3.40 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.63B | $361.02B | -$358.39B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | MRK REV | ADMA GROSS % | MRK GROSS % | ADMA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $65.01B | 57.4% | 74.8% | $27.8M | $12.36B |
| FY 2024 | $426.5M | $64.17B | 51.5% | 76.3% | $110.4M | $18.10B |
| FY 2023 | $258.2M | $60.12B | — | — | $8.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
MRK // BETA 0.92